The Claimants challenged the validity of the Defendant’s supplementary protection certificate SPC/GB05/041 for a product described in the SPC as ‘Composition containing both Tenofovir disoproxil, optionally in the form of a pharmaceutically acceptable salt, hydrate, tautomer or solvate, together with Emtricitabine’. The SPC covers a product which is marketed by Gilead under the trade mark Truvada
Citations:
[2018] EWHC 2416 (Pat)
Links:
Jurisdiction:
England and Wales
Intellectual Property
Updated: 11 June 2022; Ref: scu.628713